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Twelve males with fragile-X syndrome between the ages of three and 28 years underwent
assessment ofthyroid function. All 12 subjects demonstrated normal baseline values for thyroid
stimulating hormone (TSH), thyroxine, thyroid binding globulin (TBG), and estimated free
thyroxine (EFT). Relative to a control group reported in the literature, however, the fragile-X
subjects exhibited a blunted TSH response tothyrotropin releasing hormone (TRH). This finding
suggests the presence of subtle dysfunction within the hypothalamic-pituitary-thyroid axis.
Elevated baseline prolactin levels were also observed among the fragile-X subjects. These results
support previous reports of hypothalamic-pituitary abnormalities among fragile-X syndrome
males.
INTRODUCTION
Fragile-X syndrome is an X-linked disorder which rivals Down's syndrome as the
most common genetic cause of mental retardation. The presence of the Xq27 fragile
site has been associated with a characteristic clinical phenotype, which includes a setof
unique facial features and macro-orchidism in males [1]. It has been hypothesized that
the macro-orchidism offragile-X males may result from abnormal thyroid metabolism
[2]. This hypothesis is consistent with the association ofprecocious testicular enlarge-
ment and primary hypothyroidism described among pre-pubertal boys [3-7].
Several investigators have studied the thyroid functioning of fragile-X syndrome
males. The age groups have been diverse, spanning early childhood to middle adult-
hood. A total of53 subjects werereported in eight studies and all demonstrated normal
thyroxine levels [2,8-14]. In addition, 24 of 28 fragile-X males evaluated by four of
these investigators manifested normal, baseline TSH levels [2,9,11,13]. Shapiro et al.,
however, reported that four oftheir ten adult subjects had elevated TSH levels despite
normal T3, T4, and free T4 values [2]. It is of note that two ofthese four men also had
depressed testosterone levels.
The hypothalamic-pituitary regulation of thyroid metabolism has been studied
through the use of TRH stimulation testing. Wilson et al. evaluated 13 two- to
35-year-old fragile-X males and reported that all 13 manifested a significantly blunted
TSH response following a TRH dose of 7 ,ug/kg [13]. Subject data were compared
with normative values reported by Foley et al. [15]. O'Hare et al. found that three of
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TABLE 1
Clinical Data: Fragile-X Syndrome Subjects
Testa
Tanner Volume BSLN Delta BSLN Delta
S CA I.O. Stage (ml) T4b TBCb EFTb TSH TSH PRL PRL
1 3-2 89 1 1.5 9.4 24.7 1.8 2.0 - 15.0
2 5-2 80 1 1.0 8.0 19.6 1.9 2.0 18 7.0 19
3 7-6 67 1 2.25 6.7 18.6 1.7 2.0 21.0
4 11-3 55 2 8.0 7.9 25.8 1.4 1.3 16.5 10 63
5 12-4 45 2 15.0 8.3 23.1 1.7 2.7 7 7.1 12.5
6 15-6 44 3 17.5 7.9 22.9 1.6 3.0 16 14.0 27
7 15-8 42 3 19.5 6.3 22.8 1.3 2.3 15 13.8 65.3
8 16-0 34 4 35 6.1 23.8 1.3 4.5 1 17.3 0.53
9 16-3 38 4 39.0 7.9 24.4 1.5 4.0 22.0
10 18-0 44 5 24.0 9.5 24.8 1.8 3.5 18.1 7.3 52.9
11 25-2 53 5 50.0 5.9 24.1 1.1 2.4 12.5 20.5 19
12 28-2 45 5 38.5 5.8 21.4 1.3 2.0 9 10.0 55
S, subject
CA, chronological age in years and months
Test Volume, mean testicularvolume in ml
BSLN TSH, baseline TSH measurements in gU/ml (mean of several values, which may be slightly
different from the pre-TSH value)
Delta TSH, peak TSH value - pre-TRH value
BSLN PRL, baseline prolactin measurements in ng/ml (mean of several values which may be slightly
different from the pre-PRL value)
Delta PRL, peak PRLvalue - pre-PRL value
aNormative Data (tenth to ninetieth percentiles) adapted from [17,20]
Tanner Stage Tenth Percentile Ninetieth Percentile
Prepubertal (<11 years) 1 2
Stage 2 3 13
Stage 3 5 17
Stage 4 7 19
Stage 5 12 23
bNormative Values
T4: 4.6-9.2,ug/dl TBC: 16.8-25.7 Ag/dl EFT: 1.0-2.1 ng/dl
five fragile-X adults demonstrated virtually no response to parenterally administered
TRH [14]. The details ofthe procedure were not reported, however.
These findings suggest that, although fragile-X syndrome males appear to be
clinically euthyroid, subtle abnormalities within the hypothalamic-pituitary-thyroid
axis may be present.
SUBJECTS AND METHODS
Twelve males with fragile-X syndrome between the ages of three and 28 years
participated in the study. All subjects were residing in either family or group homes.
Cytogenetic assessments were conducted as described by Lubs et al., and involved the
examination ofa minimum 50 lymphocytes cultured in medium 199 with 2 percent calf
serum [16]. Each subject received thorough physical and psychological assessments.
Clinical data are presented in Table 1. The degree of intellectual impairment experi-
enced by the subjects ranged from mild to moderate levels of mental retardation, as
assessed by performance on the Stanford-Binet. All subjects were in good physical
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health and free from general medical or neurological disease. Three subjects were
pre-pubertal (Tanner stage 1) and nine were pubertal (Tanner stages 2 through 5).
Testicular volume measurements were made using a Prader orchidometer [17] or by
direct measurement, using the equation for ellipsoids, ir/6 x length x (width)2
[18,19]. Macro-orchidism was present in eight ofthe nine pubertal subjects and in one
ofthe three pre-pubertal subjects, based on available norms [17,20].
Baseline assessments of thyroid status were conducted during outpatient visits and
TRH stimulation tests during brief inpatient hospitalizations on the Children's or the
Adult Clinical Research Center of Yale-New Haven Hospital. Baseline laboratory
studies were obtained for all 12 subjects and included measurement of serum thyrox-
ine, thyroxine binding globulin (TBG), and estimated free thyroxine (EFT), as
described by Seligson and Seligson [21,22]. In addition, baseline values also were
obtained for TSH-modification of the method of Odell et al. [23] and for prolactin
(PRL)-modification ofthe method ofSinha et al. [24].
Hypothalamic-pituitary-thyroid axis functioning was assessed in nine subjects,
utilizing the TRH stimulation test. Following baseline determinations, 7 ,ug/kg of
purified TRH was administered intravenously. Serial serum specimens for TSH and
prolactin were collected at baseline, 30 minutes, 60 minutes, 90 minutes, and 120
minutes, in order to identify the highest (peak) value. The standard procedure for
assessing pituitary responsiveness was followed, namely, the calculation of the maxi-
mum change (delta) in serum TSH following TRH administration (peak TSH
value - pre-TRH value) [25]. Statistical analyses wereemployed for the evaluation of
differences between the fragile-X subjects and 20 control subjects reported by Foley et
al. [15]. The Foley et al. study and the present one employed the sameprocedure, using
assay techniques developed during the same period of time. The Foley et al. report
included data on individual subjects and was used for comparison with fragile-X
subjects by Wilson et al. [13]. T-tests were used for the comparison of baseline TSH




All 12 subjects demonstrated T4, TBG, and EFT values which were within the
normal range (refer to Table 1). Negative correlations were observed between age and
both serum T4and EFT levels (r = -0.57 and -0.74, respectively). Theseontogenetic
changes are similar to those which occur within the normal population [26,27].
Clinical examination of the subjects also was consistent with the presence of a
euthyroid state.
Pituitary Functioning-Tonic State
Tonic pituitary functioning relevant to thyroid status may be inferred from an
examination of baseline TSH and PRL levels. All subjects demonstrated TSH levels
within the normal range, as reported by our laboratory. When compared with 20
normal children and adolescents studied by Foley et al., however, our fragile-X group
exhibited significantly higher baseline levels of prolactin (t = 3.71, p < 0.001) [15].
This result contrasts with baseline TSH levels which wereequivalent for the two groups
(t = 1.23, p = 0.23). Tonic pituitary functioning was equivalent across the ages and






















0 30 60 90 120 FIG. 1. TRH stimulation test: Serum TSH and
Minutes Following TRH Administration prolactin responses ofthe fragile-X subjects.
Hypothalamic-Pituitary Axis Functioning
The overallpattern ofthe pituitary response to TRH stimulation was normal, with a
relatively rapid rise ofboth TSH and PRL to peakvalues by 30 minutes and a return to
pre-TRH values by 120 minutes following TRH administration (Fig. 1) [28,29]. In
addition, the magnitude of both the TSH and PRL response remained essentially
constant across the age range of our sample and that of Foley et al. (r = -0.29 and
-0.1 1, respectively), consistent with findings for the general child and adult popula-
tion [25,28,29].
There were no significant group differences with regard to the PRL response (delta
PRL) (t = 0.38;, DF = 26, p = 0.70). The fragile-X group, however, exhibited a
significantly lower TSH response (delta TSH) than that demonstrated by the normal
controls reported by Foley et al. (t = -2.39, DF = 27,p = 0.02). Within our sample,
there was a tendency for the TSH response to correlate negatively with testicular
volume (r= -0.49).
DISCUSSION
The present study examined hypothalamic-pituitary-thyroid function within a sam-
ple of fragile-X subjects representative of the developmental spectrum. Our fragile-X
subjects exhibited normal thyroid function, including normal T4, TBG, and EFT
values, as well as a normal, age-related decrement in the magnitude ofT4 and EFT. In
addition, they appeared to exhibit a relatively typical pattern of hypothalamic-
pituitary response; however, hypothalamic-pituitary regulation may be subtly disor-
dered. The fragile-X subjects demonstrated significantly higher baseline PRL values
than the control subjects reported by Foley et al. [15]. No significant groupdifferences
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were observed in the PRL response to TRH stimulation. The fragile-X subjects did,
however, exhibit decreased TSHresponsiveness to TRH, suggesting dysfunction at the
pituitary level under conditions ofmaximal stimulation.
Beforediscussing possibleinterpretations ofthesefindings, comment should be made
regarding the use ofliterature controls. Because ofthe potential for several additional
sources of experimental variance associated with the use of literature control data
(differences in procedures, assays, and the like), findings should be interpreted
cautiously and regarded as preliminary. The present study was designed to identify
potential abnormalities in the central regulation of thyroid functioning among frag-
ile-X subjects warranting more intensive study (including the addition of a more
traditional control group). The Foley et al. study was chosen for comparison with our
data because it employed the same procedure (administration of 7 mcg/kg of TRH
with similar time measurements for TSH), used a radioimmunoassay developed during
the same timeperiod as thatused in ourstudy (late 1960s toearly 1970s), and had been
used for comparison with fragile-X subjects in a previous study [13]. Although assay
differences may be present for the two studies, it is likely that they are relatively small
(there were nosignificantgroupdifferencesinbaselineTSHvalues: t = 1.23, DF = 27,
p = 0.23). It is of note that recent reviews of thyroid function reference studies from
that same era for discussions of normative values (including the Foley et al. study),
reflecting the time period during which the bulk of such studies were performed
[25,28,29].
In considering the findings of the present study, several explanations regarding
pathophysiology are possible. Hypothyroidism secondary to pituitary insufficiency has
been associated with a subnormal TSH response to TRH [30]. In the syndrome of
isolated TSH deficiency, for example, TRH stimulation results in a blunted TSH
response yet a normal PRL response [31]. Furthermore, the hypothyroid state, itself,
has been noted to result in hyperprolactinemia [32,33]. The subjects in the present
study, however, demonstrated normal thyroid indices, making such an explanation of
the findings unlikely. Thyrotoxicosis is, perhaps, the most frequent cause of a subnor-
mal TSH response to TRH [31]. Signs, symptoms, and laboratory studiessuggestiveof
hyperthyroidism were, however, lacking in the subjects under investigation.
Arnetz et al. have reported that theTRH-stimulated PRL responsedecreasesduring
the sixth decade (although the TSH response remains stable) [32]. Foley et al. found
no age-related changes in either the TSH or the PRL response within an age range of
four to 13 years [15]. Similar findings wereobtained for thefragile-X subjects, three to
28 years of age. Therefore, the group differences in the TSH response noted in the
present study cannot be ascribed to the older age ofthe fragile-X subjects.
The findings of this study include a tendency for subjects with greater degrees of
macro-orchidism to exhibit lower pituitary reserve (i.e., a decreased TSH response to
TRH stimulation). This observation is quite interesting, given the association between
hypothyroidismand premature testicular enlargement in pre-pubertal boys [3-7]. The
majority of the 17 macro-orchid boys reported in these studies had primary hypothy-
roidism (with secondary elevations ofserum TSH and gonadotropins).
The results of the present study suggest that subtle abnormalities may exist within
the hypothalamic-pituitary axis of fragile-X syndrome males, leading to elevated
baseline PRL levels and subnormal pituitary TSH reserve. Should these findings be
confirmed by future studies which include more suitable controls, a search can begin
for the factors that underlie both the testicular and the thyroid abnormalities (presum-
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ably operating at the hypothalamic-pituitary level). An hereditary form ofcongenital
hypothyroidism has been linked to the short arm of chromosome 8. It would be most
interesting, although premature, to speculate that a similar thyroid abnormality may
result from aberrant geneticexpression either within thefragile-X siteitselfor within a
closely linked locus. Future research may answer these most interesting questions.
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